Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Movement Disorders

• Publication date

  2005-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/mds.20362PMID 15580550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olfaction in neurodegenerative disorder.

  2006cited by this paper
• Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths

  2005cited by this paper
• Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms

  2005cited by this paper
• Amygdala pathology in Parkinson's disease

  2004cited by this paper
• Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

  2004cited by this paper
• Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system

  2004cited by this paper
• A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease

  2004cited by this paper
• Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material

  2004cited by this paper
• Parhnson’s Disease: Neuron Loss in the Nucleus Basah Without Concomitant Alzheimer’s Disease

  2004cited by this paper
• Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease

  2004cited by this paper
• Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses

  2004cited by this paper
• α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

  2003cited by this paper
• The effects of pramipexole in REM sleep behavior disorder

  2003cited by this paper
• Initial agonist treatment of Parkinson disease

  2003cited by this paper
• α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

  2003cited by this paper
• The prevalence of migraine in neurologists

  2003cited by this paper
• Growth Hormone and Bone Health

  2003cited by this paper
• Oxidative stress in Parkinson's disease

  2003cited by this paper
• Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.

  2003cited by this paper
• Slowing Parkinson’s disease progression

  2003cited by this paper
• Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease

  2003cited by this paper
• Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease

  2003cited by this paper
• Diabetes, oxidative stress, and antioxidants: A review

  2003cited by this paper
• Olfaction in neurodegenerative disorder

  2003cited by this paper
• Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease

  2003cited by this paper
• Levodopa Is Toxic to Dopamine Neurons in an in Vitro but Not an in Vivo Model of Oxidative Stress

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

  2003cited by this paper
• Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome*

  2002cited by this paper
• Oxidative damage and cytogenetic analysis in leukocytes of Parkinson’s disease patients

  2002cited by this paper
• Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys

  2002cited by this paper
• Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy.

  2002cited by this paper
• Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)

  2002cited by this paper
• Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.

  2002cited by this paper
• Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death.

  2002cited by this paper
• Where Does Parkinson Disease Pathology Begin in the Brain?

  2002cited by this paper
• Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases

  2002cited by this paper
• Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease.

  2002cited by this paper
• Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease.

  2002cited by this paper
• An inflammatory review of Parkinson's disease.

  2002cited by this paper
• Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease

  2002cited by this paper
• Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

  2002cited by this paper
• Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.

  2002cited by this paper
• REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease

  2002cited by this paper
• Parkinson’s disease: the thalamic components of the limbic loop are severely impaired by α-synuclein immunopositive inclusion body pathology

  2002cited by this paper
• The cytotoxicity of dopamine may be an artefact of cell culture

  2002cited by this paper
• Herpes simplex virus type 1 encephalitis is associated with elevated levels of F2-isoprostanes and F4-neuroprostanes

  2002cited by this paper
• Selective loss of pyramidal neurons in the pre‐supplementary motor cortex in Parkinson's disease

  2002cited by this paper
• Frequency of bowel movements and the future risk of Parkinson’s disease

  2001cited by this paper
• Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell

  2001cited by this paper
• Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

  2001cited by this paper
• New insights into progressive supranuclear palsy.

  2001cited by this paper
• α-Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei

  2001cited by this paper
• Oxidation and generation of hydrogen peroxide by thiol compounds in commonly used cell culture media.

  2001cited by this paper
• Chronic L‐DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6‐OHDA or FeCl3 nigrostriatal lesions

  2001cited by this paper
• Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover.

  2001cited by this paper
• Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult

  2001cited by this paper
• Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.

  2001cited by this paper
• The In Vitro Cytotoxicity of Ascorbate Depends on the Culture Medium Used to Perform the Assay and Involves Hydrogen Peroxide

  2001cited by this paper
• Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients

  2001cited by this paper
• REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson's disease: is there a need for polysomnography?

  2001cited by this paper
• Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct

  2001cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.

  2000cited by this paper
• The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity

  2000cited by this paper
• Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease

  2000cited by this paper
• alpha-synuclein promotes mitochondrial deficit and oxidative stress.

  2000cited by this paper
• α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress

  2000cited by this paper
• Accumulation of NACP/α-synuclein in Lewy body disease and multiple system atrophy

  2000cited by this paper
• Decreased striatal dopaminergic innervation in REM sleep behavior disorder

  2000cited by this paper
• Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.

  2000cited by this paper
• Increased Brain Synthesis of Prostaglandin E2 and F2‐Isoprostane in Human and Experimental Transmissible Spongiform Encephalopathies

  2000cited by this paper
• New dopaminergic neurons in Parkinson's disease striatum.

  2000cited by this paper
• Pathoanatomy of Parkinson’s disease

  2000cited by this paper
• Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases.

  2000cited by this paper
• Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease

  2000cited by this paper
• Degeneration of the centré median–parafascicular complex in Parkinson's disease

  2000cited by this paper
• A discrete pontine ischemic lesion could cause REM sleep behavior disorder

  2000cited by this paper
• Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease

  2000cited by this paper
• Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity.

  2000cited by this paper
• Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies.

  2000cited by this paper
• Parkinson’s disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system

  2000cited by this paper
• The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

  2000cited by this paper
• Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons.

  1999cited by this paper
• Tyrosine hydroxylase immunoreactive structures in the aged human olfactory bulb and olfactory peduncle.

  1999cited by this paper
• Lewy body–type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases

  1999cited by this paper
• Oxidative Stress and Motor Neurone Disease

  1999cited by this paper
• Abnormal performance on the PD test battery by asymptomatic first-degree relatives

  1999cited by this paper
• Oxidative Stress in Huntington's Disease

  1999cited by this paper
• The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.

  1999cited by this paper
• Mitochondrial dysfunction in parkinson's disease

  1998cited by this paper
• Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET

  1998cited by this paper
• Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity

  1998cited by this paper
• Apomorphine does not influence olfactory thresholds in Parkinson's disease.

  1998cited by this paper
• Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease

  1998cited by this paper
• A dopamine-synthesizing cell group demonstrated in the human basal forebrain by dual labeling immunohistochemical technique of tyrosine hydroxylase and aromatic L-amino acid decarboxylase.

  1998cited by this paper
• Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

  1998cited by this paper
• Oxidative damage to DNA in plaques of MS brains

  1998cited by this paper
• Protein Nitration in Parkinson's Disease

  1998cited by this paper
• Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration

  1998cited by this paper

• Crosstalk between Oxidative Stress and Inflammation Caused by Noise and Air Pollution—Implications for Neurodegenerative Diseases

  2024cites this paper
• Parkinson's disease progression is multifaceted: Evidence for the underlying benchmarks.

  2024cites this paper
• The Effect of Acetic Acid-Induced Pain in Parkinson's Disease Model in Zebrafish.

  2023cites this paper
• The noradrenergic subtype of Parkinson disease: from animal models to clinical practice

  2023cites this paper
• Pathogenetic factors in Parkinson disease and novel experimental therapies

  2022cites this paper
• Expression analysis of vitamin D receptor and its related long non-coding RNAs in peripheral blood of patients with Parkinson's disease

  2022cites this paper
• Association between Anemia and Risk of Parkinson Disease

  2021cites this paper
• Quercetin exhibits potent antioxidant activity, restores motor and non-motor deficits induced by rotenone toxicity

  2021cites this paper
• Assessing the Effects of Vitamin D on Neural Network Function in Patients With Parkinson’s Disease by Measuring the Fraction Amplitude of Low-Frequency Fluctuation

  2021cites this paper
• Editorial Comment: Sexual Dysfunction in Parkinson Disease: A Multicenter Italian Cross-sectional Study on a Still Overlooked Problem

  2021cites this paper
• Abnormal Vision-Based Displacement Perception in Parkinson’s Disease

  2021cites this paper
• LRRK2 at the Crossroad of Aging and Parkinson’s Disease

  2021cites this paper
• The VDR FokI (rs2228570) polymorphism is involved in Parkinson's disease.

  2021cites this paper
• Editorial comment: Clinical Recommendations From the European Society for Sexual Medicine Exploring Partner Expectations, Satisfaction in Male and Phalloplasty Cohorts, the Impact of Penile Length, Girth and Implant Type, Reservoir Placement, and the Influence of Comorbidities and Social Circumstanc

  2021cites this paper
• The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson’s disease

  2020cites this paper
• Chemically Induced Models of Parkinson’s Disease: History and Perspectives for the Involvement of Ferroptosis

  2020cites this paper
• Common Myths and Misconceptions That Sidetrack Parkinson Disease Treatment, to the Detriment of Patients.

  2020cites this paper
• Origins of atrophy in Parkinson linked to early onset and local transcription patterns

  2020cites this paper
• Anemia and the risk of Parkinson’s disease in Korean older adults: A nationwide population-based study

  2020cites this paper
• The Chinese Herb Codonopsis pilosula Isolate Isorhapontigenin protects against oxidative stress injury by inhibiting the activation of PI3K/Akt signaling pathway.

  2020cites this paper
• Heterogeneity of Incipient Atrophy Patterns in Parkinson’s Disease

  2018cites this paper
• Methylene Blue Ameliorates Olfactory Dysfunction and Motor Deficits in a Chronic MPTP/Probenecid Mouse Model of Parkinson's Disease.

  2018cites this paper
• Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats

  2018cites this paper
• Neurodegeneration, Neuroregeneration, and Neuroprotection in Psychiatric Disorders.

  2017cites this paper
• TRPM2 Promotes Neurotoxin MPP+/MPTP-Induced Cell Death

  2016cites this paper
• The improvement of MAO-B inhibitors in Parkinson’s disease is clinically irrelevant: a review

  2016cites this paper
• Oxidative stress, cellular senescence and ageing

  2016cites this paper
• The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.

  2015cites this paper
• Parkinson's disease as a result of aging

  2015cites this paper
• Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson's disease.

  2015cites this paper
• Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats

  2015cites this paper
• Increased Risk of Parkinson Disease in Patients With Carbon Monoxide Intoxication

  2015cites this paper
• Associations between Severity of Motor Function and Nonmotor Symptoms in Parkinson's Disease: A Post Hoc Analysis of the RECOVER Study

  2014cites this paper
• Clinical REM sleep behavior disorder and motor subtypes in Parkinson's disease: a questionnaire-based study.

  2014cites this paper
• Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein.

  2013cites this paper
• Oxidative Stress in Aging-Matters of the Heart and Mind

  2013cites this paper
• Neuropathologie van de Ziekte van Parkinson De progressie van Lewy inclusies vanaf de nervus vagus tot aan de cerebrale cortex

  2013cites this paper
• he effect of aging on dopamine release and metabolism during sevoflurane nesthesia in rat striatum : An in vivo microdialysis study

  2012cites this paper
• The effect of aging on dopamine release and metabolism during sevoflurane anesthesia in rat striatum: an in vivo microdialysis study.

  2012cites this paper
• Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

  2012cites this paper
• ROLE OF GDNF AND ITS CROSS-TALK WITH OTHER GROWTH FACTORS IN THE DOPAMINERGIC SYSTEM

  2012cites this paper
• Alpha-synuclein in the neurodegenerative mechanisms of Parkinson's disease and dementia with Lewy bodies

  2012influential citation
• Występowanie dyskinez w przebiegu choroby Parkinsona leczonej preparatami lewodopy

  2012cites this paper
• Nonmotor symptom complex of Parkinson's disease--an under-recognized entity.

  2011cites this paper
• Kerttu Koskenniemi Proteomic Characterization of Probiotic Lactobacillus rhamnosus GG 3 / 2012 Laura Lahti FGF Signaling in Neurogenesis and Patterning of the Developing Midbrain and Anterior Hindbrain

  2011cites this paper
• Cheaper, simpler, and better: tips for treating seniors with Parkinson disease.

  2011cites this paper
• Mathematical Models: Interactions Between Serotonin and Dopamine in Parkinson’s Disease

  2011cites this paper
• L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?

  2011cites this paper
• Rasagiline, Parkinson neuroprotection, and delayed-start trials

  2010cites this paper
• Seniors with Parkinson's Disease: Initial Medical Treatment

  2010cites this paper
• Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration

  2010cites this paper
• The Dual Hit Theory Revisited

  2009cites this paper
• New molecular avenues in Parkinson's disease therapy.

  2009cites this paper
• Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.

  2009cites this paper
• The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

  2009cites this paper
• Parkinson's Disease

  2009cites this paper
• [Non-motor disorders in Parkinson's disease].

  2008cites this paper
• Invited Article: Nervous system pathology in sporadic Parkinson disease

  2008cites this paper
• Porträt einer Arzneipflanze

  2008cites this paper
• Neuroanatomy and pathology of sporadic Parkinson's disease.

  2008cites this paper
• Trastornos no motores en la enfermedad de Parkinson

  2008cites this paper
• Neurotrophic factors as a therapeutic target for Parkinson's disease

  2008cites this paper
• Facoltà di Medicina e Chirurgia Dottorato in Medicina Molecolare, XIX Ciclo

  2008cites this paper
• Levodopa for the treatment of Parkinson's disease.

  2008cites this paper
• Incidental Lewy body disease and preclinical Parkinson disease.

  2008cites this paper
• Oxidative and Inflammatory Pathways in Parkinson’s Disease

  2008cites this paper
• Synergistic neurotoxic effects of arsenic and dopamine in human dopaminergic neuroblastoma SH-SY5Y cells.

  2008cites this paper
• The mechanism for paraquat toxicity involves oxidative stress and inflammation : a model for Parkinson's disease

  2007cites this paper
• Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease.

  2007cites this paper
• Parkinson's disease: a dual‐hit hypothesis

  2007influential citation
• Beating a dead horse

  2007cites this paper
• Oxidative stress and Parkinson's disease.

  2007cites this paper
• Molecular pathways and genetic aspects of Parkinson’s disease: from bench to bedside

  2007cites this paper
• Potential of the Rotigotine Transdermal Patch for Patients with Advanced Parkinson's Disease

  2007cites this paper
• The Effect of Truncated Human α-Synuclein (1–120) on Dopaminergic Cells in a Transgenic Mouse Model of Parkinson's Disease

  2007cites this paper
• Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons

  2007cites this paper
• ACNR MJ07:Layout 1

  2007influential citation
• Levodopa for the treatment of Parkinson’s disease: current perspectives

  2006cites this paper
• Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

  2006cites this paper
• Non-motor symptoms in Parkinson's disease: An underdiagnosed problem

  2006cites this paper
• Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases

  2006cites this paper
• Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.

  2006cites this paper
• Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra

  2006cites this paper
• New pharmacologic horizons in the treatment of Parkinson disease

  2006cites this paper
• Pathology associated with sporadic Parkinson's disease--where does it end?

  2006cites this paper
• Non-motor symptoms of Parkinson's disease: diagnosis and management.

  2006cites this paper
• The pathogenesis of cell death in Parkinson's disease

  2006cites this paper
• Medical management of advanced Parkinson's disease.

  2006cites this paper
• Acute neurotoxic effects of the fungal metabolite ochratoxin-A.

  2006cites this paper
• The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential

  2005cites this paper
• The Evolution and Potential of the National Parkinson Organizations: A Brief Overview

  2004cites this paper
• MavMatrix MavMatrix

  year unknowncites this paper